Akums Drugs and Pharmaceuticals Limited — Important, 24-12-2024: Agreements

Akums Drugs and Pharmaceuticals Limited has entered into a long-term contract manufacturing and supply agreement with a leading global pharma company for selected pharmaceutical formulations intended for the European market. The agreement, worth approximately Euro 200 million (INR 1,760 crores), includes an upfront payment of Euro 100 million (INR 880 crores) to support product development and site approval. Commercial production is set to commence in 2027 and will continue until 2032, with European approvals for Akums’ oral liquid manufacturing site expected by 2026. This move aligns with Akums' strategy to expand its footprint in regulated markets, enhancing collaboration opportunities with other global firms and leveraging its existing EU-approved facilities. The partnership underscores Akums' manufacturing excellence and its commitment to global market expansion, potentially opening new revenue streams in the future. Investors should view this agreement positively as it positions Akums for significant growth in the European pharma sector.